Challenges and prospects of CYP2C19 genotype-guided clopidogrel therapy from the perspective of precision medicine
Frontiers in Pharmacology · 24.03.2026 · 17
DOI: 10.3389/fphar.2026.1711350 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 24.03.2026. Verfasst von Zixiao Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Hebei North University, Zhangjiakou, China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In the era of precision medicine, dual antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor is the standard strategy for patients after percutaneous coronary intervention (PCI). Clopidogrel, as a widely used representative drug, has its efficacy significantly influenced by CYP2C19 genetic polymorphisms, leading to poor metabolism in some patients, insufficient exposure to active metabolites, and increased risk of ischemic events. In theory, CYP2C19 genotyping to guide individualized antiplatelet therapy could help optimize the clinical selection of P2Y12 inhibitors and improve prognosis. However, current evidence and guidelines do not support its use as a routine test for post-PCI patients, reflecting multiple challenges in clinical translation. From the perspective of precision medicine, this article systematically reviews the main problems and clinical application dilemmas of CYP2C19 genotyping in guiding clopidogrel therapy, including controversies and uncertainties in randomized controlled trials (RCTs) evidence, neglect of rare alleles, complexity of metabolism regulated by polygenic and clinical factors, and limited predictive value for low platelet reactivity. Finally, this paper prospects future research directions and clinical translation prospects, aiming to provide a theoretical reference for promoting individualized antiplatelet therapy and balancing thrombosis and bleeding risks.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
- The First Hospital of Jilin University, Changchun, China.
- Cangzhou Central Hospital, Cangzhou, China.
Zitieren
APA
Wang, Z., Fu, X., & Zhang, G. (2026). Challenges and prospects of CYP2C19 genotype-guided clopidogrel therapy from the perspective of precision medicine. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1711350
Vancouver
Wang Z, Fu X, Zhang G. Challenges and prospects of CYP2C19 genotype-guided clopidogrel therapy from the perspective of precision medicine. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1711350
BibTeX
@article{Wang2026,
author = {Wang, Zixiao and Fu, Xiangkai and Zhang, Guoying},
title = {Challenges and prospects of CYP2C19 genotype-guided clopidogrel therapy from the perspective of precision medicine},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1711350}
}
EUVIMED